Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 345 E Main St WARSAW IN 46580-2746 |
Tel: | N/A |
Website: | https://www.zimmerbiomet.com/en |
IR: | See website |
Key People | ||
Ivan Tornos President, Chief Executive Officer, Director | Suketu P. Upadhyay Chief Financial Officer, Executive Vice President - Finance, Operations and Supply Chain | Wilfred Van Zuilen President - Europe, Middle East and Africa |
Sang Yi President, Asia Pacific | Lori Winkler Chief Human Resource Officer, Senior Vice President | Chad F. Phipps Senior Vice President, General Counsel, Secretary |
Rachel Ellingson Senior Vice President, Chief Strategy Officer, Executive Officer | Paul A. Stellato Chief Accounting Officer, Vice President, Controller |
Business Overview |
Zimmer Biomet Holdings, Inc. is a global medical technology company. Its segments include Americas, EMEA, and Asia Pacific. The Company designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; craniomaxillofacial and thoracic (CMFT) products; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its other product category primarily includes its robotic, surgical and bone cement products. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee, and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System, and G7 Acetabular System. Its S.E.T. product category includes sports medicine, biologics, foot and others. |
Financial Overview |
For the fiscal year ended 31 December 2023, Zimmer Biomet Holdings Inc revenues increased 7% to $7.39B. Net income before extraordinary items increased from $290.2M to $1.02B. Revenues reflect Americas segment increase of 8% to $4.62B, EMEA segment increase of 9% to $1.59B, Americas segment increase of 8% to $4.62B, EMEA segment increase of 9% to $1.59B. Net income benefited from Unallocated segment loss decrease of 15% to $1.62B. |
Employees: | 18,000 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $32,548M as of Dec 31, 2023 |
Annual revenue (TTM): | $7,394M as of Dec 31, 2023 |
EBITDA (TTM): | $2,425M as of Dec 31, 2023 |
Net annual income (TTM): | $1,024M as of Dec 31, 2023 |
Free cash flow (TTM): | $691.50M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $5,352M as of Dec 31, 2023 |
Shares outstanding: | 205,084,022 as of Feb 14, 2024 |
Index Membership: | S&P 500 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |